×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| Krishna Institute of Medical S | 3856.0 | 588.0 | 3734.0 | 1.47 | 29,450 | 79.8 |
| J.B.CHEMICALS & PHARMACEUTICAL | 10538.0 | 1978.7 | 10399.0 | 12.48 | 27067 | 39.5 |
| Dr. Lal Pathlabs Limited | 6670.0 | 1293.0 | 6407.0 | 15.49 | 26766 | 52.2 |
Krishna Institute of Medical Sciences Limited, with Security Code 543308, is a leading player in the Hospital industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 283.5 | 293.4 | 298.9 | 316.2 | 302.1 | 304.8 | 327.4 | 363.3 | 347.5 | 373.4 |
| Expenses | 193.5 | 189.0 | 206.6 | 218.0 | 214.6 | 218.6 | 233.6 | 252.2 | 244.6 | 275.9 |
| Operating Profit | 90.0 | 104.3 | 92.3 | 98.3 | 87.5 | 86.3 | 93.8 | 111.1 | 102.9 | 97.5 |
| OPM % | 31.73% | 35.56% | 30.89% | 31.08% | 28.96% | 28.31% | 28.65% | 30.58% | 29.61% | 26.11% |
| Other Income | 7.2 | 5.0 | 3.8 | 3.6 | 4.2 | 3.9 | 5.3 | 6.6 | 20.6 | 12.2 |
| Interest | 0.2 | 0.2 | 0.1 | 0.1 | 1.2 | 2.3 | 3.8 | 4.6 | 6.7 | 12.5 |
| Depreciation | 11.3 | 11.2 | 12.1 | 12.8 | 12.8 | 20.4 | 13.7 | 14.0 | 14.9 | 17.5 |
| Profit before tax | 85.6 | 98.0 | 84.0 | 89.0 | 77.7 | 67.5 | 81.6 | 99.1 | 101.9 | 79.7 |
| Tax % | -24.7% | -23.8% | -25.4% | -25.7% | -24.9% | -28.6% | -25.6% | 27.1% | -24.9% | 26.2% |
| Net Profit | 64.5 | 74.7 | 62.6 | 66.2 | 58.4 | 48.2 | 60.7 | 72.2 | 76.5 | 58.8 |
| EPS in Rs | 1.61 | 1.87 | 1.57 | 1.65 | 1.46 | 1.2 | 1.52 | 1.8 | 1.91 | 1.47 |
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 562.2 | 575.9 | 606.0 | 652.5 | 605.8 | 633.8 | 688.4 | 777.3 | 772.4 | 796.9 |
| Expenses | 411.0 | 412.7 | 449.0 | 475.2 | 458.8 | 475.0 | 509.0 | 559.2 | 585.2 | 598.9 |
| Operating Profit | 151.2 | 163.2 | 157.1 | 177.3 | 147.0 | 158.8 | 179.4 | 218.1 | 187.2 | 198.0 |
| OPM % | 26.89% | 28.34% | 25.92% | 27.17% | 24.26% | 25.06% | 26.06% | 28.06% | 24.24% | 24.85% |
| Other Income | 6.5 | 4.9 | 3.1 | 2.9 | 3.3 | 3.8 | 4.6 | 5.0 | 17.8 | 15.3 |
| Interest | 11.5 | 5.4 | 9.3 | 8.9 | 12.4 | 16.4 | 17.9 | 19.9 | 25.7 | 26.7 |
| Depreciation | 33.3 | 35.4 | 32.3 | 32.6 | 35.4 | 46.3 | 39.0 | 41.0 | 44.7 | 52.6 |
| Profit before tax | 112.8 | 127.3 | 118.6 | 138.6 | 102.5 | 100.0 | 127.1 | 162.2 | 134.6 | 123.2 |
| Tax % | -27.5% | -22.5% | -26.9% | -26.9% | -25.2% | -28.5% | 25.1% | -25.6% | -31.3% | -20.8% |
| Net Profit | 81.8 | 98.7 | 86.7 | 101.3 | 76.6 | 71.5 | 95.2 | 120.7 | 92.5 | 106.1 |
| EPS in Rs | 1.9 | 2.33 | 2.02 | 2.3 | 1.8 | 1.64 | 2.16 | 2.68 | 2.22 | 0 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 12% |
| 3 Years: | 7% |
| TTM: | 13% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 19% |
| 3 Years: | 2% |
| TTM: | 26% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 38% |
| 1 Year: | 78% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 22% |
| 3 Years: | 23% |
| TTM: | 21% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 27% |
| 3 Years: | 4% |
| TTM: | 22% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 38% |
| 1 Year: | 78% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|